Maravai Lifesciences Holdings, Inc. Financials

MRVI

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Maravai Lifesciences Holdings, Inc. (MRVI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 36/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Maravai Lifesciences Holdings, Inc. has an operating margin of -90.9%, meaning the company retains $-91 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -10.9% the prior year.

Growth

Maravai Lifesciences Holdings, Inc.'s revenue declined 10.3% year-over-year, from $288.9M to $259.2M. This contraction results in a growth score of 0/100.

Leverage

Maravai Lifesciences Holdings, Inc. carries a low D/E ratio of 0.89, meaning only $0.89 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 78/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 7.53, Maravai Lifesciences Holdings, Inc. holds $7.53 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While Maravai Lifesciences Holdings, Inc. generated $7.5M in operating cash flow, capex of $29.7M consumed most of it, leaving -$22.2M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Neutral

4/9

Maravai Lifesciences Holdings, Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

-0.05x

For every $1 of reported earnings, Maravai Lifesciences Holdings, Inc. generates $-0.05 in operating cash flow ($7.5M OCF vs -$144.8M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

-4.9x

Maravai Lifesciences Holdings, Inc. earns $-4.9 in operating income for every $1 of interest expense (-$235.6M vs $47.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

$259.2M

YoY-10.3%

5Y CAGR+12.6%

Maravai Lifesciences Holdings, Inc. generated $259.2M in revenue in fiscal year 2024. This represents a decrease of 10.3% from the prior year.

EBITDA

-$187.2M

YoY-2275.6%

Maravai Lifesciences Holdings, Inc.'s EBITDA was -$187.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 2275.6% from the prior year.

Free Cash Flow

-$22.2M

YoY-136.6%

Maravai Lifesciences Holdings, Inc. generated -$22.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 136.6% from the prior year.

Net Income

-$144.8M

YoY-21.7%

Maravai Lifesciences Holdings, Inc. reported -$144.8M in net income in fiscal year 2024. This represents a decrease of 21.7% from the prior year.

EPS (Diluted)

$-1.05

YoY-16.7%

Maravai Lifesciences Holdings, Inc. earned $-1.05 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 16.7% from the prior year.

Cash & Debt

$322.4M

YoY-43.9%

5Y CAGR+67.2%

Maravai Lifesciences Holdings, Inc. held $322.4M in cash against $290.5M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

N/A

Gross Margin

41.8%

YoY-6.7pp

5Y CAGR-11.5pp

Maravai Lifesciences Holdings, Inc.'s gross margin was 41.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 6.7 percentage points from the prior year.

Operating Margin

-90.9%

YoY-80.0pp

5Y CAGR-107.7pp

Maravai Lifesciences Holdings, Inc.'s operating margin was -90.9% in fiscal year 2024, reflecting core business profitability. This is down 80.0 percentage points from the prior year.

Net Margin

-55.9%

YoY-14.7pp

5Y CAGR-52.8pp

Maravai Lifesciences Holdings, Inc.'s net profit margin was -55.9% in fiscal year 2024, showing the share of revenue converted to profit. This is down 14.7 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$19.2M

YoY+11.2%

5Y CAGR+39.6%

Maravai Lifesciences Holdings, Inc. invested $19.2M in research and development in fiscal year 2024. This represents an increase of 11.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$29.7M

YoY-54.8%

5Y CAGR+11.6%

Maravai Lifesciences Holdings, Inc. invested $29.7M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 54.8% from the prior year.

MRVI Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$259.2M-10.3%	$288.9M-67.3%	$883.0M+10.5%	$799.2M+181.3%	$284.1M+98.5%	$143.1M
Cost of Revenue	$150.9M+1.4%	$148.7M-12.0%	$169.0M+20.2%	$140.6M+76.5%	$79.6M+19.1%	$66.8M
Gross Profit	$108.3M-22.7%	$140.2M-80.4%	$714.0M+8.4%	$658.7M+222.2%	$204.4M+168.0%	$76.3M
R&D Expenses	$19.2M+11.2%	$17.3M-5.9%	$18.4M+20.7%	$15.2M+63.6%	$9.3M+156.5%	$3.6M
SG&A Expenses	$161.8M+6.9%	$151.4M+17.1%	$129.3M+29.2%	$100.1M+6.2%	$94.2M+94.9%	$48.4M
Operating Income	-$235.6M-644.5%	-$31.6M-105.5%	$574.2M+3.5%	$554.6M+362.6%	$119.9M+399.8%	$24.0M
Interest Expense	$47.7M+3.9%	$45.9M+124.8%	$20.4M-32.5%	$30.3M-1.6%	$30.7M+2.6%	$30.0M
Income Tax	-$1.9M-100.2%	$756.1M+1143.4%	$60.8M-1.1%	$61.5M+2035.9%	$2.9M+541.7%	-$652K
Net Income	-$144.8M-21.7%	-$119.0M-154.1%	$220.2M+21.0%	$182.0M+104.6%	$89.0M+2090.4%	-$4.5M
EPS (Diluted)	$-1.05-16.7%	$-0.90-153.9%	$1.67+7.1%	$1.56-33.9%	$2.36+7966.7%	$-0.03

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$41.6M-12.2%	$47.4M+1.2%	$46.9M-17.2%	$56.6M-18.5%	$69.4M+8.2%	$64.2M-13.4%	$74.1M+10.9%	$66.9M
Cost of Revenue	$36.0M-9.2%	$39.6M+1.3%	$39.1M+5.3%	$37.2M-3.7%	$38.6M+0.6%	$38.3M+9.2%	$35.1M-4.3%	$36.7M
Gross Profit	$5.7M-27.2%	$7.8M+0.6%	$7.7M-60.2%	$19.4M-37.1%	$30.8M+19.3%	$25.8M-33.8%	$39.0M+29.3%	$30.2M
R&D Expenses	$3.8M-21.3%	$4.9M-0.1%	$4.9M+7.2%	$4.6M-7.4%	$4.9M-2.1%	$5.0M+9.5%	$4.6M+5.7%	$4.3M
SG&A Expenses	$35.4M-8.2%	$38.6M-2.5%	$39.6M-4.1%	$41.2M+1.7%	$40.6M-0.8%	$40.9M+6.3%	$38.5M-1.0%	$38.9M
Operating Income	-$41.0M+38.1%	-$66.3M-34.8%	-$49.2M-30.4%	-$37.7M-180.5%	-$13.4M+28.7%	-$18.9M-163.8%	-$7.2M+53.6%	-$15.4M
Interest Expense	$6.8M+0.4%	$6.8M+0.5%	$6.8M-39.8%	$11.3M-5.7%	$11.9M+9.9%	$10.9M-29.5%	$15.4M+32.3%	$11.6M
Income Tax	-$92K+97.9%	-$4.3M-2746.9%	$162K+2414.3%	-$7K+99.7%	-$2.4M-998.5%	$271K-100.0%	$766.2M+14129.8%	-$5.5M
Net Income	-$25.6M+35.4%	-$39.6M-32.2%	-$29.9M-15.6%	-$25.9M-164.6%	-$9.8M+19.0%	-$12.1M+88.6%	-$106.0M-1539.7%	-$6.5M
EPS (Diluted)	$-0.18+33.3%	$-0.27-28.6%	$-0.210.0%	$-0.21-200.0%	$-0.07+22.2%	$-0.09+88.8%	$-0.80-1500.0%	$-0.05

MRVI Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$1.0B-32.2%	$1.5B-34.8%	$2.3B+19.0%	$1.9B+51.0%	$1.3B	N/A
Current Assets	$429.1M-38.7%	$699.9M-17.5%	$847.9M+14.6%	$740.0M+123.2%	$331.6M	N/A
Cash & Equivalents	$322.4M-43.9%	$575.0M-9.0%	$632.1M+14.7%	$551.3M+133.4%	$236.2M+856.2%	$24.7M
Inventory	$50.1M-2.6%	$51.4M+19.1%	$43.2M-16.3%	$51.6M+54.8%	$33.3M	N/A
Accounts Receivable	$38.5M-29.5%	$54.6M-60.6%	$138.6M+18.0%	$117.5M+130.3%	$51.0M	N/A
Goodwill	$159.9M-51.0%	$326.0M+14.9%	$283.7M+85.7%	$152.8M-31.9%	$224.3M	N/A
Total Liabilities	$683.0M-36.2%	$1.1B-22.2%	$1.4B+0.3%	$1.4B+23.0%	$1.1B	N/A
Current Liabilities	$57.0M-34.9%	$87.5M-20.6%	$110.1M+17.5%	$93.8M-28.3%	$130.8M	N/A
Long-Term Debt	$290.5M-44.0%	$518.7M-0.6%	$522.0M-0.5%	$524.6M-0.8%	$528.6M	N/A
Total Equity	$325.3M-21.9%	$416.8M-23.6%	$545.2M+72.8%	$315.5M+256.5%	$88.5M-38.8%	$144.6M
Retained Earnings	$140.9M-50.7%	$285.7M-29.4%	$404.8M+119.3%	$184.6M+21511.4%	$854K	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$849.2M-5.3%	$897.0M-6.5%	$959.8M-4.8%	$1.0B-30.2%	$1.4B-0.1%	$1.4B-2.9%	$1.5B-34.4%	$2.3B
Current Assets	$325.9M-9.4%	$359.8M-4.4%	$376.3M-12.3%	$429.1M-37.0%	$681.5M+2.0%	$667.9M-4.6%	$699.9M-0.1%	$700.9M
Cash & Equivalents	$243.6M-9.8%	$269.9M-5.3%	$285.1M-11.6%	$322.4M-43.8%	$573.2M+2.0%	$561.7M-2.3%	$575.0M-0.8%	$579.6M
Inventory	$45.3M-2.9%	$46.7M-6.2%	$49.8M-0.6%	$50.1M+1.5%	$49.3M-1.0%	$49.8M-3.0%	$51.4M+4.6%	$49.1M
Accounts Receivable	$22.5M-19.2%	$27.9M-2.1%	$28.5M-26.0%	$38.5M+10.9%	$34.7M-5.3%	$36.7M-32.8%	$54.6M+19.6%	$45.7M
Goodwill	$129.4M0.0%	$129.4M-19.0%	$159.9M0.0%	$159.9M-51.0%	$326.0M0.0%	$326.0M0.0%	$326.0M0.0%	$326.0M
Total Liabilities	$603.7M-4.3%	$631.1M-4.3%	$659.1M-3.5%	$683.0M-32.3%	$1.0B-2.4%	$1.0B-3.4%	$1.1B-22.1%	$1.4B
Current Liabilities	$61.6M-11.6%	$69.7M+10.3%	$63.2M+10.9%	$57.0M-17.0%	$68.6M+16.3%	$59.0M-32.5%	$87.5M+11.8%	$78.3M
Long-Term Debt	$287.4M-0.4%	$288.4M-0.4%	$289.5M-0.3%	$290.5M-43.8%	$517.1M-0.2%	$517.9M-0.2%	$518.7M-0.2%	$519.5M
Total Equity	$245.4M-7.7%	$265.9M-11.6%	$300.6M-7.6%	$325.3M-25.2%	$434.7M+5.9%	$410.7M-1.5%	$416.8M-19.7%	$519.3M
Retained Earnings	$45.8M-35.8%	$71.4M-35.7%	$110.9M-21.3%	$140.9M-46.6%	$263.9M-3.6%	$273.7M-4.2%	$285.7M-27.1%	$391.7M

MRVI Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	$7.5M-94.1%	$126.2M-76.4%	$536.0M+45.4%	$368.6M+142.2%	$152.2M+531.1%	$24.1M
Capital Expenditures	$29.7M-54.8%	$65.6M+283.6%	$17.1M+15.1%	$14.8M-41.6%	$25.4M+48.2%	$17.1M
Free Cash Flow	-$22.2M-136.6%	$60.7M-88.3%	$518.9M+46.7%	$353.7M+179.0%	$126.8M+1719.7%	$7.0M
Investing Cash Flow	-$24.3M+80.1%	-$122.3M+54.3%	-$267.6M-353.3%	$105.7M+1641.2%	$6.1M+135.4%	-$17.1M
Financing Cash Flow	-$235.7M-285.8%	-$61.1M+67.4%	-$187.5M-17.9%	-$159.0M-398.9%	$53.2M+1377.0%	-$4.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$0	$0-100.0%	$33.7M	$0

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$15.2M-47.6%	-$10.3M-9.3%	-$9.4M+35.9%	-$14.6M-184.0%	$17.4M+305.9%	-$8.5M-208.7%	$7.8M-45.0%	$14.2M
Capital Expenditures	$2.9M+1.8%	$2.9M-45.1%	$5.2M-10.5%	$5.8M-38.8%	$9.6M+68.6%	$5.7M-66.3%	$16.8M+6.1%	$15.8M
Free Cash Flow	-$18.1M-37.6%	-$13.1M+10.2%	-$14.6M+28.6%	-$20.5M-360.0%	$7.9M+155.8%	-$14.1M-56.9%	-$9.0M-442.4%	-$1.7M
Investing Cash Flow	-$2.9M+9.6%	-$3.2M+86.0%	-$23.1M-369.1%	-$4.9M+20.2%	-$6.2M-45.7%	-$4.2M+67.1%	-$12.9M+16.9%	-$15.5M
Financing Cash Flow	-$8.2M-437.7%	-$1.5M+68.7%	-$4.9M+97.9%	-$236.2M-103691.7%	$228K+140.7%	-$560K-219.1%	$470K-40.0%	$783K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

MRVI Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	41.8%-6.7pp	48.5%-32.3pp	80.9%-1.5pp	82.4%+10.5pp	72.0%+18.7pp	53.3%
Operating Margin	-90.9%-80.0pp	-10.9%-76.0pp	65.0%-4.4pp	69.4%+27.2pp	42.2%+25.4pp	16.8%
Net Margin	-55.9%-14.7pp	-41.2%-66.1pp	24.9%+2.2pp	22.8%-8.5pp	31.3%+34.4pp	-3.1%
Return on Equity	N/A	N/A	40.4%-17.3pp	57.7%-42.8pp	100.5%	N/A
Return on Assets	-14.4%-6.4pp	-8.0%-17.6pp	9.7%+0.2pp	9.5%+2.5pp	7.0%	N/A
Current Ratio	7.53-0.5	8.00+0.3	7.70-0.2	7.89+5.4	2.54	N/A
Debt-to-Equity	0.89-0.4	1.24+0.3	0.96-0.7	1.66-4.3	5.97	N/A
FCF Margin	-8.6%-29.6pp	21.0%-37.8pp	58.8%+14.5pp	44.3%-0.4pp	44.6%+39.8pp	4.9%

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	13.6%-2.8pp	16.4%-0.1pp	16.5%-17.8pp	34.3%-10.1pp	44.4%+4.1pp	40.3%-12.4pp	52.6%+7.5pp	45.1%
Operating Margin	-98.6%+41.3pp	-139.8%-34.9pp	-104.9%-38.3pp	-66.7%-47.3pp	-19.4%+10.0pp	-29.4%-19.8pp	-9.6%+13.4pp	-23.1%
Net Margin	-61.4%+22.1pp	-83.5%-19.6pp	-63.9%-18.1pp	-45.8%-31.7pp	-14.1%+4.7pp	-18.8%+124.1pp	-142.9%-133.3pp	-9.7%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-3.0%+1.4pp	-4.4%-1.3pp	-3.1%-0.5pp	-2.6%-1.9pp	-0.7%+0.2pp	-0.8%+6.3pp	-7.1%-6.8pp	-0.3%
Current Ratio	5.29+0.1	5.16-0.8	5.96-1.6	7.53-2.4	9.93-1.4	11.32+3.3	8.00-1.0	8.96
Debt-to-Equity	1.17+0.1	1.08+0.1	0.96+0.1	0.89-0.3	1.19-0.1	1.26+0.0	1.24+0.2	1.00
FCF Margin	-43.4%-15.7pp	-27.7%+3.5pp	-31.2%+5.0pp	-36.2%-47.6pp	11.3%+33.4pp	-22.0%-9.9pp	-12.2%-9.7pp	-2.5%

Similar Companies

Mimedx Group Inc MDXG

$758.3M

Cormedix CRMD

$578.3M

180 Life Sciences Corp ATNF

$1.1B

Oric Pharmaceuticals, Inc. ORIC

$972.9M

Verve Therapeutics, Inc. VERV

$994.0M

Frequently Asked Questions

What is Maravai Lifesciences Holdings, Inc.'s annual revenue?

Maravai Lifesciences Holdings, Inc. (MRVI) reported $259.2M in total revenue for fiscal year 2024. This represents a -10.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Maravai Lifesciences Holdings, Inc.'s revenue growing?

Maravai Lifesciences Holdings, Inc. (MRVI) revenue declined by 10.3% year-over-year, from $288.9M to $259.2M in fiscal year 2024.

Is Maravai Lifesciences Holdings, Inc. profitable?

No, Maravai Lifesciences Holdings, Inc. (MRVI) reported a net income of -$144.8M in fiscal year 2024, with a net profit margin of -55.9%.

What is Maravai Lifesciences Holdings, Inc.'s earnings per share (EPS)?

Maravai Lifesciences Holdings, Inc. (MRVI) reported diluted earnings per share of $-1.05 for fiscal year 2024. This represents a -16.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Maravai Lifesciences Holdings, Inc.'s EBITDA?

Maravai Lifesciences Holdings, Inc. (MRVI) had EBITDA of -$187.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Maravai Lifesciences Holdings, Inc. have?

As of fiscal year 2024, Maravai Lifesciences Holdings, Inc. (MRVI) had $322.4M in cash and equivalents against $290.5M in long-term debt.

What is Maravai Lifesciences Holdings, Inc.'s gross margin?

Maravai Lifesciences Holdings, Inc. (MRVI) had a gross margin of 41.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Maravai Lifesciences Holdings, Inc.'s operating margin?

Maravai Lifesciences Holdings, Inc. (MRVI) had an operating margin of -90.9% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Maravai Lifesciences Holdings, Inc.'s net profit margin?

Maravai Lifesciences Holdings, Inc. (MRVI) had a net profit margin of -55.9% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Maravai Lifesciences Holdings, Inc.'s free cash flow?

Maravai Lifesciences Holdings, Inc. (MRVI) generated -$22.2M in free cash flow during fiscal year 2024. This represents a -136.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Maravai Lifesciences Holdings, Inc.'s operating cash flow?

Maravai Lifesciences Holdings, Inc. (MRVI) generated $7.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Maravai Lifesciences Holdings, Inc.'s total assets?

Maravai Lifesciences Holdings, Inc. (MRVI) had $1.0B in total assets as of fiscal year 2024, including both current and long-term assets.

What are Maravai Lifesciences Holdings, Inc.'s capital expenditures?

Maravai Lifesciences Holdings, Inc. (MRVI) invested $29.7M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Maravai Lifesciences Holdings, Inc. spend on research and development?

Maravai Lifesciences Holdings, Inc. (MRVI) invested $19.2M in research and development during fiscal year 2024.

What is Maravai Lifesciences Holdings, Inc.'s current ratio?

Maravai Lifesciences Holdings, Inc. (MRVI) had a current ratio of 7.53 as of fiscal year 2024, which is generally considered healthy.

What is Maravai Lifesciences Holdings, Inc.'s debt-to-equity ratio?

Maravai Lifesciences Holdings, Inc. (MRVI) had a debt-to-equity ratio of 0.89 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Maravai Lifesciences Holdings, Inc.'s return on assets (ROA)?

Maravai Lifesciences Holdings, Inc. (MRVI) had a return on assets of -14.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Maravai Lifesciences Holdings, Inc.'s Piotroski F-Score?

Maravai Lifesciences Holdings, Inc. (MRVI) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Maravai Lifesciences Holdings, Inc.'s earnings high quality?

Maravai Lifesciences Holdings, Inc. (MRVI) has an earnings quality ratio of -0.05x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Maravai Lifesciences Holdings, Inc. cover its interest payments?

Maravai Lifesciences Holdings, Inc. (MRVI) has an interest coverage ratio of -4.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Maravai Lifesciences Holdings, Inc.?

Maravai Lifesciences Holdings, Inc. (MRVI) scores 36 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.